Dr. Uldrick on Rituximab Plus Liposomal Doxorubicin in HIV-Infected Patients With KSHV-MCD

Thomas S. Uldrick, MD
Published: Thursday, Jun 18, 2015



Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease (KSHV-MCD).

KSHV is able to infect endothelial cells, B-cells, and concurrent tumors, Uldrick says. Results from a study showed that 95% of patients treated with rituximab plus liposomal doxorubicin will have a complete resolution of symptoms, while nearly 90% will have normalization of all laboratory abnormalities that are caused by MCD.

Twenty-two patients were treated with rituximab plus liposomal doxorubicin. Long-term follow-up of this data demonstrates that patients present with a wide range of symptoms, such as fevers, anemia, edema, and swelling. Researchers sought to determine which baseline factors predicted good long-term outcomes in patients, especially those with HIV-associated and KSHV factors. The only factor that predicted survival was advanced KS, Uldrick adds.

The 5-year overall survivals was 91% for patients without advanced KS and 56% for patients with advanced KS. Additionally, 70% of patients were disease-free after a median of 3 cycles of treatment.

<<< View more from the 13th International Conference on Malignant Lymphoma



Thomas S. Uldrick, MD, staff clinician, HIV and AIDS Malignancy Branch, Center for Cancer Research at the National Institutes of Health, discusses long-term data from a study examining rituximab plus liposomal doxorubicin in HIV-infected patients with Kaposi sarcoma (KS) herpes virus-associated multicentric Castleman disease (KSHV-MCD).

KSHV is able to infect endothelial cells, B-cells, and concurrent tumors, Uldrick says. Results from a study showed that 95% of patients treated with rituximab plus liposomal doxorubicin will have a complete resolution of symptoms, while nearly 90% will have normalization of all laboratory abnormalities that are caused by MCD.

Twenty-two patients were treated with rituximab plus liposomal doxorubicin. Long-term follow-up of this data demonstrates that patients present with a wide range of symptoms, such as fevers, anemia, edema, and swelling. Researchers sought to determine which baseline factors predicted good long-term outcomes in patients, especially those with HIV-associated and KSHV factors. The only factor that predicted survival was advanced KS, Uldrick adds.

The 5-year overall survivals was 91% for patients without advanced KS and 56% for patients with advanced KS. Additionally, 70% of patients were disease-free after a median of 3 cycles of treatment.

<<< View more from the 13th International Conference on Malignant Lymphoma


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x